Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration

Simply Wall St.06-18

Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644770590?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-06-18 14:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644770590","market":"hk","top_or_hot":-1,"title":"Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration","media":"Simply Wall St.","content":"<div>\n<p>Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/bio-techne-tech-stock-could-be-104-undervalued-after-refeyn\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-18 14:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/bio-techne-tech-stock-could-be-104-undervalued-after-refeyn><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/bio-techne-tech-stock-could-be-104-undervalued-after-refeyn\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/bio-techne-tech-stock-could-be-104-undervalued-after-refeyn","article_id":"2644770590","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/bio-techne-tech-stock-could-be-104-undervalued-after-refeyn","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644770590","pubTimestamp":1781763978,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution.\nSee our latest analysis for Bio-Techne.\nAlongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4585":"ETF&股票定投概念","TECH":"Bio-Techne","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","TECH.AU":"GLOBAL X MORNINGSTAR GLOBAL","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4588":"碎股","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"Refeyn合作后，Bio-Techne(TECH)股票可能被低估10.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.5,"TECH.AU":1.5},"content_text":"Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits against a 5 year total shareholder return decline of 49.38%. This suggests short term momentum has picked up after a weaker multi year stretch. If this kind of biotech tools story interests you, it may be worth widening your search through our screener of 40 healthcare AI stocks. With Bio-Techne trading at US$55.00 against an average analyst price target of US$61.31 and one estimate of fair value near US$61.42, the question is simple: is there real upside left here or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 10.4% Undervalued With Bio-Techne stock at $55.00 against a narrative fair value of $61.42, the most followed story in the market argues the current price sits below those assumptions.  The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher margin core business segments and growth pillars, supporting both immediate operating margin improvement (expected 100–200 basis point expansion) and higher future earnings. Accelerated innovation and product launches in automated proteomic instrumentation (for example, Leo Simple Western and Maurice) and digital platforms are driving high margin, high throughput product adoption, increasingly embedding the company's solutions in regulated pharma manufacturing workflows.  Read the complete narrative. Want to see what sits behind that fair value for Bio-Techne? The narrative leans heavily on compounding earnings, improving profitability, and a rich future earnings multiple that the market is not fully reflecting yet. Result: Fair Value of $61.42 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear pressure points for the Bio-Techne story, including weaker biotech funding and potential tariff or pricing changes that could weigh on customer demand. Find out about the key risks to this Bio-Techne narrative. Another View: Bio-Techne stock through earnings multiples The fair value story for Bio-Techne hinges on future earnings, but current pricing tells a different tale. At a P/E of 78.6x, compared with 64.6x for peers and 34.9x for the wider Life Sciences industry, and a fair ratio of 24.6x, the stock screens as expensive. This raises the question of whether this premium aligns with your investment approach. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TECH P/E Ratio as at Jun 2026Next Steps If this mix of optimism and concern around Bio-Techne leaves you undecided, now is a good time to review the numbers yourself and decide where you stand, starting with 1 key reward and 1 important warning sign Looking for more investment ideas beyond Bio-Techne? If the Bio-Techne story has sharpened your focus, do not stop here. Broadening your search now could reveal opportunities that fit your style even better.  Target potential mispricings by scanning for companies that look attractively valued using the 48 high quality undervalued stocks. Build a steadier income stream by reviewing candidates in the 8 dividend fortresses. Prioritise resilience by focusing on businesses highlighted in the 65 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bio-Techne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644770590","isCrawlerRequest":true}